SG11201907870VA - Compositions and methods for inhibition of lineage specific proteins - Google Patents
Compositions and methods for inhibition of lineage specific proteinsInfo
- Publication number
- SG11201907870VA SG11201907870VA SG11201907870VA SG11201907870VA SG11201907870VA SG 11201907870V A SG11201907870V A SG 11201907870VA SG 11201907870V A SG11201907870V A SG 11201907870VA SG 11201907870V A SG11201907870V A SG 11201907870VA SG 11201907870V A SG11201907870V A SG 11201907870VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- boston
- compositions
- suite
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 102000018697 Membrane Proteins Human genes 0.000 abstract 2
- 108010052285 Membrane Proteins Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 239000002254 cytotoxic agent Substances 0.000 abstract 2
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 241000282461 Canis lupus Species 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 abstract 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 abstract 1
- 230000006037 cell lysis Effects 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- 230000009033 hematopoietic malignancy Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Modifiedor deleted epitope No Lysis -1 cc 00 O C N (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 September 2018 (07.09.2018) WIPO I PCT omit VIII °nolo omioolimmoiflo oimIE (10) International Publication Number WO 2018/160768 Al AML Cell Lysis (51) International Patent Classification: A61K 35/12 (2015.01) CO7K 14/705 (2006.01) A61K 35/14 (2015.01) CO7K 16/28 (2006.01) A61K 35/17 (2015.01) C12N 5/078 (2010.01) A61K 35/38 (2015.01) C12N 5/0789 (2010.01) (21) International Application Number: PCT/US2018/020327 (22) International Filing Date: 28 February 2018 (28.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/464,975 28 February 2017 (28.02.2017) US (71) Applicant: VOR BIOPHARMA, INC. [US/US]; 501 Boylston Street, Suite 6102, Boston, MA 02116 (US). (72) Inventors: BOLEN, Joseph; 501 Boylston Street, Suite 6102, Boston, MA 02116 (US). RADOVIC-MORENO, Aleksandar, Filip; 501 Boylston Street, Suite 6102, Boston, MA 02116 (US). LYDEARD, John; 501 Boylston Street, Suite 6102, Boston, MA 02116 (US). (74) Agent: WITTE-GARCIA, Chelsea, E.; Wolf, Green- field & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (54) Title: COMPOSITIONS AND METHODS FOR INHIBITION LINEAGE SPECIFIC PROTEINS FIGURE 3 B Targeting CD33+AML Cells No Binding to Edited Donor Graft Cells (57) : Disclosed herein are compositions, methods, and kits for use in treating hematopoietic malignancies, the compositions, methods, and kits comprise a cytotoxic agent targeting cells expressing a lineage-specific cell-surface protein and a population of hematopoietic cells that express the lineage-specific cell-surface protein, the hematopoietic cells being manipulated such that they do not bind the cytotoxic agent. [Continued on next page] WO 2018/160768 Al MIDEDIMOMMIDIREIDIDEMIEHEIHISIONVOIMIE EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762464975P | 2017-02-28 | 2017-02-28 | |
PCT/US2018/020327 WO2018160768A1 (en) | 2017-02-28 | 2018-02-28 | Compositions and methods for inhibition lineage specific proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907870VA true SG11201907870VA (en) | 2019-09-27 |
Family
ID=63370206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907870VA SG11201907870VA (en) | 2017-02-28 | 2018-02-28 | Compositions and methods for inhibition of lineage specific proteins |
Country Status (13)
Country | Link |
---|---|
US (1) | US11975029B2 (en) |
EP (1) | EP3589291A4 (en) |
JP (2) | JP7386082B2 (en) |
KR (1) | KR20190141657A (en) |
CN (1) | CN110662554A (en) |
AU (2) | AU2018229351B2 (en) |
BR (1) | BR112019017751A2 (en) |
CA (1) | CA3054808A1 (en) |
IL (1) | IL268895A (en) |
MX (1) | MX2019010196A (en) |
RU (1) | RU2019130504A (en) |
SG (1) | SG11201907870VA (en) |
WO (1) | WO2018160768A1 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108290939B (en) | 2015-10-16 | 2023-01-13 | 纽约市哥伦比亚大学理事会 | Compositions and methods for inhibiting lineage specific antigens |
CN110662554A (en) | 2017-02-28 | 2020-01-07 | Vor生物制药股份有限公司 | Compositions and methods for inhibiting lineage specific proteins |
WO2019046285A1 (en) * | 2017-08-28 | 2019-03-07 | The Trustees Of Columbia University In The City Of New York | Cd33 exon 2 deficient donor stem cells for use with cd33 targeting agents |
BR112021003670A2 (en) | 2018-08-28 | 2021-05-18 | Vor Biopharma, Inc. | genetically modified hematopoietic stem cells and their uses |
US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
KR20210138603A (en) * | 2019-02-13 | 2021-11-19 | 빔 테라퓨틱스, 인크. | Modified immune cells with an adenosine deaminase base editor for modifying nucleobases in a target sequence |
WO2020168088A1 (en) * | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating glycogen storage disease type 1a |
EP3973057A1 (en) | 2019-05-23 | 2022-03-30 | Vor Biopharma, Inc. | Compositions and methods for cd33 modification |
CN114729367A (en) | 2019-08-28 | 2022-07-08 | Vor生物制药股份有限公司 | Compositions and methods for CLL1 modification |
EP4022064A1 (en) | 2019-08-28 | 2022-07-06 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
EP4034561A2 (en) * | 2019-09-27 | 2022-08-03 | Starkage Therapeutics | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
US11723926B2 (en) | 2019-09-27 | 2023-08-15 | Starkage Therapeutics | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
WO2021081244A1 (en) * | 2019-10-22 | 2021-04-29 | Fred Hutchinson Cancer Research Center | Base editor-mediated cd33 reduction to selectively protect therapeutic cells |
CN115348973A (en) * | 2020-03-31 | 2022-11-15 | 弗莱德哈钦森癌症中心 | Chimeric antigen receptor targeting CD33 |
JP2023540277A (en) | 2020-08-28 | 2023-09-22 | ブイオーアール バイオファーマ インコーポレーテッド | Compositions and methods for CD123 modification |
JP2023540276A (en) | 2020-08-28 | 2023-09-22 | ブイオーアール バイオファーマ インコーポレーテッド | Compositions and methods for CLL1 modification |
EP4211245A1 (en) | 2020-09-14 | 2023-07-19 | Vor Biopharma Inc. | Compositions and methods for cd5 modification |
JP2023541457A (en) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Compounds and methods for CD38 modification |
US20240033290A1 (en) | 2020-09-18 | 2024-02-01 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
WO2022067240A1 (en) | 2020-09-28 | 2022-03-31 | Vor Biopharma, Inc. | Compositions and methods for cd6 modification |
WO2022072643A1 (en) | 2020-09-30 | 2022-04-07 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
EP4243858A1 (en) * | 2020-11-13 | 2023-09-20 | Vor Biopharma Inc. | Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors |
JP2024502820A (en) | 2020-12-31 | 2024-01-23 | ブイオーアール バイオファーマ インコーポレーテッド | Compositions and methods for CD34 gene modification |
CN115443333A (en) * | 2021-04-27 | 2022-12-06 | 上海驯鹿生物技术有限公司 | Gene-edited hematopoietic stem cell and combined application thereof and CAR-T cell |
EP4380693A1 (en) | 2021-08-06 | 2024-06-12 | Universität Basel | Discernible cell surface protein variants for use in cell therapy |
WO2023086422A1 (en) | 2021-11-09 | 2023-05-19 | Vor Biopharma Inc. | Compositions and methods for erm2 modification |
WO2023111311A1 (en) | 2021-12-16 | 2023-06-22 | Universität Basel | Discernible cell surface protein variants of cd117 for use in cell therapy |
CA3240875A1 (en) | 2021-12-23 | 2023-06-29 | Stefanie Urlinger | Discernible cell surface protein variants of cd45 for use in cell therapy |
WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
CN116850210B (en) * | 2023-01-17 | 2024-05-31 | 武汉大学 | Compositions and methods for treating acute myeloid leukemia |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101658083B1 (en) | 2007-10-19 | 2016-09-30 | 시애틀 지네틱스, 인크. | Cd19 binding agents and uses thereof |
CA2781522A1 (en) * | 2009-10-19 | 2011-04-28 | Tristem Trading (Cyprus) Limited | Treatment using reprogrammed mature adult cells |
EP2596011B1 (en) | 2010-07-21 | 2018-10-03 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a hla locus |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
DK3401400T3 (en) | 2012-05-25 | 2019-06-03 | Univ California | METHODS AND COMPOSITIONS FOR RNA CONTROLLED TARGET DNA MODIFICATION AND FOR RNA-CONTROLLED TRANCE CRITICAL MODULATION |
WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
EP2833591A1 (en) | 2013-07-31 | 2015-02-04 | Siemens Aktiengesellschaft | Subsea data communication interface unit |
EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
DK3105317T3 (en) | 2014-02-14 | 2019-01-14 | Cellectis | Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells |
MX370272B (en) | 2014-03-19 | 2019-12-09 | Cellectis | Cd123 specific chimeric antigen receptors for cancer immunotherapy. |
KR102170533B1 (en) | 2014-04-03 | 2020-10-27 | 셀렉티스 | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
WO2015157070A2 (en) | 2014-04-09 | 2015-10-15 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating cystic fibrosis |
WO2015164740A1 (en) | 2014-04-24 | 2015-10-29 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
WO2015195547A1 (en) | 2014-06-16 | 2015-12-23 | University Of Washington | Methods for controlling stem cell potential and for gene editing in stem cells |
US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
AR101829A1 (en) | 2014-07-21 | 2017-01-18 | Novartis Ag | CANCER TREATMENT USING A CLL-1 CHEMERIC ANTIGEN RECEIVER |
CA2955154C (en) | 2014-07-21 | 2023-10-31 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
CA2960769A1 (en) | 2014-09-16 | 2016-03-24 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
KR101799975B1 (en) | 2014-10-31 | 2017-11-21 | 에스케이씨하이테크앤마케팅(유) | Color gamut enhancing and brightness compensation film for liquid crystal display and liquid crystal display comprising same |
EP3025719B1 (en) | 2014-11-26 | 2018-09-26 | Miltenyi Biotec GmbH | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
JP7068821B2 (en) | 2014-12-03 | 2022-05-17 | アジレント・テクノロジーズ・インク | Guide RNA with chemical modification |
WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
US11014989B2 (en) | 2015-01-26 | 2021-05-25 | Cellectis | Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy |
AU2016246450B2 (en) | 2015-04-06 | 2022-03-17 | Agilent Technologies, Inc. | Chemically modified guide RNAs for CRISPR/Cas-mediated gene regulation |
EP4056588A1 (en) * | 2015-04-08 | 2022-09-14 | Novartis AG | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell |
US10293058B2 (en) | 2015-04-22 | 2019-05-21 | Curevac Ag | RNA containing composition for treatment of tumor diseases |
GB201507119D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
WO2016176651A2 (en) * | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
EP3294896A1 (en) | 2015-05-11 | 2018-03-21 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
TW201718647A (en) | 2015-06-16 | 2017-06-01 | 建南德克公司 | Anti-CLL-1 antibodies and methods of use |
CN108290939B (en) | 2015-10-16 | 2023-01-13 | 纽约市哥伦比亚大学理事会 | Compositions and methods for inhibiting lineage specific antigens |
CN108513575A (en) | 2015-10-23 | 2018-09-07 | 哈佛大学的校长及成员们 | Nucleobase editing machine and application thereof |
SG10202107602XA (en) * | 2015-11-04 | 2021-08-30 | Univ Pennsylvania | Methods and compositions for gene editing in hematopoietic stem cells |
AU2016361426B2 (en) | 2015-11-24 | 2023-02-23 | Onk Therapeutics Limited | Humanized anti-CLL-1 antibodies |
JP7208010B2 (en) * | 2016-03-29 | 2023-01-18 | ユニバーシティ オブ サザン カリフォルニア | Chimeric antigen receptor targeting cancer |
WO2017186718A1 (en) | 2016-04-25 | 2017-11-02 | Universität Basel | Allele editing and applications thereof |
US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
CA3025667A1 (en) | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
CA3029197A1 (en) | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
EP3481861A1 (en) | 2016-07-06 | 2019-05-15 | Cellectis | Sequential gene editing in primary immune cells |
MD3529262T2 (en) | 2016-10-21 | 2022-01-31 | Inst Nat Sante Rech Med | Methods for promoting t cells response |
KR20240043810A (en) * | 2016-11-02 | 2024-04-03 | 유니버시타트 바셀 | Immunologically discernible cell surface variants for use in cell therapy |
WO2018126176A1 (en) | 2016-12-30 | 2018-07-05 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
CN110662554A (en) | 2017-02-28 | 2020-01-07 | Vor生物制药股份有限公司 | Compositions and methods for inhibiting lineage specific proteins |
JP2020510439A (en) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Base-editing factor from cytosine to guanine |
SG11201908658TA (en) | 2017-03-23 | 2019-10-30 | Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
AU2018258027A1 (en) | 2017-04-24 | 2019-10-24 | Memorial Sloan Kettering Cancer Center | Anti-CD33 antibody agents |
WO2019046285A1 (en) | 2017-08-28 | 2019-03-07 | The Trustees Of Columbia University In The City Of New York | Cd33 exon 2 deficient donor stem cells for use with cd33 targeting agents |
WO2019152591A1 (en) | 2018-01-31 | 2019-08-08 | Hydroacoustics Inc. | Fluid sensor and pumpjack control system |
EP3749764A1 (en) | 2018-02-08 | 2020-12-16 | Zymergen, Inc. | Genome editing using crispr in corynebacterium |
TWI669677B (en) | 2018-03-07 | 2019-08-21 | 光陽工業股份有限公司 | Charging base management method, server for charging base management method, and charging base |
BR112021003670A2 (en) | 2018-08-28 | 2021-05-18 | Vor Biopharma, Inc. | genetically modified hematopoietic stem cells and their uses |
SG11202103832SA (en) | 2018-11-07 | 2021-05-28 | Crispr Therapeutics Ag | Anti-cd33 immune cell cancer therapy |
CA3126677A1 (en) | 2019-01-16 | 2020-07-23 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for inhibition of lineage specific antigens |
CN114072495A (en) | 2019-01-16 | 2022-02-18 | 比姆医疗股份有限公司 | Modified immune cells with enhanced antitumor activity and immunosuppressive resistance |
KR20210138603A (en) | 2019-02-13 | 2021-11-19 | 빔 테라퓨틱스, 인크. | Modified immune cells with an adenosine deaminase base editor for modifying nucleobases in a target sequence |
EP3973057A1 (en) | 2019-05-23 | 2022-03-30 | Vor Biopharma, Inc. | Compositions and methods for cd33 modification |
EA202191979A1 (en) | 2019-05-24 | 2021-11-01 | Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк | COMPOSITIONS AND METHODS FOR INHIBITING LINE-SPECIFIC ANTIGENS |
EP4022064A1 (en) | 2019-08-28 | 2022-07-06 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
CN114729367A (en) | 2019-08-28 | 2022-07-08 | Vor生物制药股份有限公司 | Compositions and methods for CLL1 modification |
-
2018
- 2018-02-28 CN CN201880026602.0A patent/CN110662554A/en active Pending
- 2018-02-28 US US16/489,407 patent/US11975029B2/en active Active
- 2018-02-28 CA CA3054808A patent/CA3054808A1/en active Pending
- 2018-02-28 EP EP18760400.4A patent/EP3589291A4/en active Pending
- 2018-02-28 AU AU2018229351A patent/AU2018229351B2/en active Active
- 2018-02-28 MX MX2019010196A patent/MX2019010196A/en unknown
- 2018-02-28 KR KR1020197028404A patent/KR20190141657A/en active IP Right Grant
- 2018-02-28 SG SG11201907870VA patent/SG11201907870VA/en unknown
- 2018-02-28 JP JP2019547641A patent/JP7386082B2/en active Active
- 2018-02-28 RU RU2019130504A patent/RU2019130504A/en unknown
- 2018-02-28 BR BR112019017751A patent/BR112019017751A2/en active Search and Examination
- 2018-02-28 WO PCT/US2018/020327 patent/WO2018160768A1/en unknown
-
2019
- 2019-08-25 IL IL26889519A patent/IL268895A/en unknown
-
2023
- 2023-11-13 JP JP2023192752A patent/JP2024019176A/en active Pending
-
2024
- 2024-04-03 AU AU2024202117A patent/AU2024202117A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20190141657A (en) | 2019-12-24 |
MX2019010196A (en) | 2019-12-19 |
JP7386082B2 (en) | 2023-11-24 |
EP3589291A1 (en) | 2020-01-08 |
EP3589291A4 (en) | 2020-11-25 |
JP2020509050A (en) | 2020-03-26 |
RU2019130504A (en) | 2021-03-30 |
US20200030381A1 (en) | 2020-01-30 |
WO2018160768A8 (en) | 2019-04-18 |
AU2018229351B2 (en) | 2024-01-04 |
CA3054808A1 (en) | 2018-09-07 |
IL268895A (en) | 2019-10-31 |
CN110662554A (en) | 2020-01-07 |
BR112019017751A2 (en) | 2020-04-07 |
AU2018229351A1 (en) | 2019-09-26 |
AU2024202117A1 (en) | 2024-05-02 |
US11975029B2 (en) | 2024-05-07 |
WO2018160768A1 (en) | 2018-09-07 |
JP2024019176A (en) | 2024-02-08 |
RU2019130504A3 (en) | 2021-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907870VA (en) | Compositions and methods for inhibition of lineage specific proteins | |
SG11201907298WA (en) | Methods and compositions for gene transfer across the vasculature | |
SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
SG11201908023YA (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
SG11201907848YA (en) | Antibodies binding to vista at acidic ph | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201807590SA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
SG11201807868VA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201909303TA (en) | Point of delivery cold slurry generation | |
SG11201907253VA (en) | Proteins binding bcma, nkg2d and cd16 | |
SG11201907646YA (en) | Proteins binding her2, nkg2d and cd16 | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
SG11201809716VA (en) | T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII | |
SG11201901634UA (en) | An hbv antigen specific binding molecules and fragments thereof | |
SG11201900085TA (en) | Modified ligand-gated ion channels and methods of use |